Spevatamig is Phanes’ anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I₂E), an emerging class of immuno-oncology (IO) agents. Spevatamig is currently in Phase 2 studies for the treatment of multiple forms of gastrointestinal cancers. The expansion of the clinical trial collaboration, originally entered in 2023, now includes spevatamig in combination with KEYTRUDA® and […]
Two dose levels of spevatamig in combination with standard of care chemotherapy are being evaluated as frontline (1L) treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in the Phase 2 study. Initial data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the efficacy signal at the 2 mg/kg dose level and […]
SAN DIEGO, May 28, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, released updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) for the American Society of Clinical Oncology (ASCO) Annual Meeting […]
SAN DIEGO, April 22, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present updated Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology […]
SAN DIEGO, April 7, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer (BTC), following dose-limiting toxicity (DLT) clearance at […]
SAN DIEGO, March 18, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present three posters from their ongoing Phase 2 clinical trial with spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47, at the American Association for Cancer Research […]
SAN DIEGO, Jan. 9, 2026 /PRNewswire/ — Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective first-line (1L) treatment in patients with CLDN18.2 positive metastatic pancreatic ductal adenocarcinoma (mPDAC) Spevatamig’s unique molecular design mitigates hematological toxicity, and improves gastrointestinal (GI) tolerability (nausea and vomiting) […]
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present their Phase 1/2 study results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of […]
SAN DIEGO, Sept. 8, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of spevatamig in combination with chemotherapy for the treatment of biliary tract carcinoma (BTC). Spevatamig is a first-in-class native […]
SAN DIEGO, May 27, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy. Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action […]
